Withdrawn by the developer due to the committee not passing the measure on evidence, a must-pass criterion.
The Risk Standardized Mortality Ratio for Late-Stage CKD and ESRD is an outcome measure to assess how well providers prevent mortality among patients with stage 4 or 5 CKD or ESRD. This measure assesses nephrology practices who care for adult Medicare Fee-for-Service (FFS) beneficiaries with late-stage CKD and ESRD.
-
-
1.5 Measure Type1.8 Level Of Analysis1.20 Testing Data Sources
-
1.14 Numerator
The measure outcome is all-cause mortality within the measurement year. Mortality is defined as death for any reason within the measurement period for patients age 19 and older with Stage 4 CKD, Stage 5 CKD, or ESRD at risk during the measurement period. Hospice enrollment is a censoring event and mortality after enrollment is not counted to the outcome.
-
1.15 Denominator
The cohort includes Medicare Fee-For-Service beneficiaries (patients) who are 19 years and older with Stage 4 CKD, Stage 5 CKD, or ESRD and who are being treated by a nephrology practice. Patients are not included if they are enrolled in Medicare hospice, or have had a kidney transplant within the past 12 months.
-
Exclusions
The measure excludes patients with metastatic and advanced cancers, defined as specific cancer-related ICD-10 codes from an inpatient encounter.
-
OLD 1.12 MAT output not attachedAttached
-
Most Recent Endorsement ActivityPrimary Care and Chronic Illness Spring 2023
-
Steward Organization Email
-
-
-
Risk AdjustmentRisk adjustment approachOffRisk adjustment approachOffConceptual model for risk adjustmentOffConceptual model for risk adjustmentOff
-
-
-
6.1.2 Current or Planned Use(s)6.1.3 Current Use(s)
-
Effective March 27, 2023, the National Quality Forum (NQF) is no longer the consensus-based entity (CBE) funded through the Centers for Medicare & Medicaid Services (CMS) National Consensus Development and Strategic Planning for Health Care Quality Measurement Contract. Battelle has been selected to oversee the endorsement & maintenance (E&M) of clinical quality and cost/resource use measures. Since the Spring 2023 cycle launched at NQF, measures submitted to this E&M cycle continued along the prior E&M protocols that were in place at time of the Spring 2023 “Intent to Submit.” Battelle took over the E&M work for the Spring 2023 cycle when developers and/or stewards submitted their full measure information, which for CBE #3754, the most recent measure specifications can be found here: https://p4qm.org/sites/default/files/2023-06/3754_-ckd_esrd_mortality.zip
To close out this E&M cycle, Battelle published the Spring 2023 measures for pre-evaluation public commenting, convened the E&M standing committees for their measure evaluation meetings, launched the Spring 2023 post-comment period, convened the E&M committees for the post-comment meeting, convened the CSAC to render a final endorsement decision, and executed the appeals period.